Cargando…

The Unique Pharmacological and Pharmacokinetic Profile of Teneligliptin: Implications for Clinical Practice

Teneligliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that was approved for the treatment of type 2 diabetes mellitus (T2DM) in Japan and Korea and is being researched in several countries. Teneligliptin is a potent, selective, and long-lasting DPP-4 inhibitor with a t(½) of approximately 24 h...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ceriello, Antonio, De Nigris, Valeria, Iijima, Hiroaki, Matsui, Takahiro, Gouda, Maki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2019
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6520312/ https://www.ncbi.nlm.nih.gov/pubmed/30982160 http://dx.doi.org/10.1007/s40265-019-01086-0

Ejemplares similares

Teneligliptin enhances the beneficial effects of GLP-1 in endothelial cells exposed to hyperglycemic conditions
por: De Nigris, Valeria, et al.
Publicado: (2017)

The dipeptidyl peptidase-4 (DPP-4) inhibitor teneligliptin functions as antioxidant on human endothelial cells exposed to chronic hyperglycemia and metabolic high-glucose memory
por: Pujadas, Gemma, et al.
Publicado: (2016)

Long‐term safety and efficacy of canagliflozin as add‐on therapy to teneligliptin in Japanese patients with type 2 diabetes
por: Kadowaki, Takashi, et al.
Publicado: (2017)

DPP-4 Inhibitors Have Different Effects on Endothelial Low-Grade Inflammation and on the M1-M2 Macrophage Polarization Under Hyperglycemic Conditions
por: De Nigris, Valeria, et al.
Publicado: (2021)

Efficacy and safety of canagliflozin as add‐on therapy to teneligliptin in Japanese patients with type 2 diabetes mellitus: Results of a 24‐week, randomized, double‐blind, placebo‐controlled trial
por: Kadowaki, Takashi, et al.
Publicado: (2017)

Efficacy and safety of teneligliptin added to canagliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: A multicentre, randomized, double‐blind, placebo‐controlled, parallel‐group comparative study
por: Kadowaki, Takashi, et al.
Publicado: (2017)

Tissue distribution of teneligliptin in rats and comparisons with data reported for other dipeptidyl peptidase‐4 inhibitors
por: Nakamaru, Yoshinobu, et al.
Publicado: (2016)

Efficacy and safety of teneligliptin
por: Singh, Awadhesh Kumar
Publicado: (2017)

Influence of FMO3 and CYP3A4 Polymorphisms on the Pharmacokinetics of Teneligliptin in Humans
por: Park, Jin-Woo, et al.
Publicado: (2021)

Teneligliptin in management of type 2 diabetes mellitus
por: Sharma, Surendra Kumar, et al.
Publicado: (2016)

Teneligliptin and “Thorough QTc study”: thorough enough?
por: Ghosal, Samit
Publicado: (2019)

Associations between eating habits and glycemic control and obesity in Japanese workers with type 2 diabetes mellitus
por: Gouda, Maki, et al.
Publicado: (2018)

Teneligliptin-induced hair loss: A case report
por: Agrawal, Prabhat K., et al.
Publicado: (2020)

Exanthematous Drug Eruption as a Side Effect of Teneligliptin
por: Sunil, Krupa A., et al.
Publicado: (2021)

Effects of teneligliptin on PDMPs and PAI-1 in patients with diabetes on hemodialysis
por: Okuda, Yoshinori, et al.
Publicado: (2016)

Therapeutic Effect of Teneligliptin in Drug-Induced Nephrotoxicity: An In-Vitro Study
por: Becerir, Tülay, et al.
Publicado: (2022)

The Possible Role of Flavonoids in the Prevention of Diabetic Complications
por: Testa, Roberto, et al.
Publicado: (2016)

Pharmacokinetics of a Fixed-Dose Combination of Teneligliptin Hydrochloride Hydrate and Modified-Release Metformin Under Fasting and Fed Conditions in Healthy Subjects
por: Goak, In Sun, et al.
Publicado: (2022)

Teneligliptin Decreases Uric Acid Levels by Reducing Xanthine Dehydrogenase Expression in White Adipose Tissue of Male Wistar Rats
por: Moriya, Chihiro, et al.
Publicado: (2016)

Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes
por: Kishimoto, Miyako
Publicado: (2013)

Diffuse erythematous rash after teneligliptin therapy: A case report
por: Agrawal, Prabhat, et al.
Publicado: (2018)

“Inflammaging” as a Druggable Target: A Senescence-Associated Secretory Phenotype—Centered View of Type 2 Diabetes
por: Prattichizzo, Francesco, et al.
Publicado: (2016)

GLP-1 reduces metalloproteinase-9 induced by both hyperglycemia and hypoglycemia in type 1 diabetes. The possible role of oxidative stress
por: Ceriello, Antonio, et al.
Publicado: (2015)

Short-term high glucose exposure impairs insulin signaling in endothelial cells
por: De Nigris, Valeria, et al.
Publicado: (2015)

SAT-173 Antiproliferative Effect of Teneligliptin on Atherosclerosis in Vascular Smooth Muscle Cell
por: Moon, Shinje, et al.
Publicado: (2019)

Teneligliptin protects against ischemia/reperfusion-induced endothelial permeability in vivo and in vitro
por: Zhang, Lei, et al.
Publicado: (2020)

The “Metabolic Memory” Theory and the Early Treatment of Hyperglycemia in Prevention of Diabetic Complications
por: Testa, Roberto, et al.
Publicado: (2017)

Teneligliptin As an Initial Therapy for Newly Diagnosed, Drug Naive Subjects With Type 2 Diabetes
por: Kutoh, Eiji, et al.
Publicado: (2014)

Efficacy and safety of teneligliptin in combination with pioglitazone in Japanese patients with type 2 diabetes mellitus
por: Kadowaki, Takashi, et al.
Publicado: (2013)

Effectiveness and Safety of Hydroxychloroquine compared to Teneligliptin in uncontrolled T2DM patients as add-on Therapy
por: Kumar, Amit, et al.
Publicado: (2019)

Pharmacological management of COVID-19 in type 2 diabetes
por: Ceriello, Antonio, et al.
Publicado: (2021)

Association between glycemic control and cardiovascular events in older Japanese adults with diabetes mellitus: An analysis of the Japanese medical administrative database
por: Yokote, Koutaro, et al.
Publicado: (2021)

Suppression of Abdominal Aortic Aneurysm Formation in Mice by Teneligliptin, a Dipeptidyl Peptidase-4 Inhibitor
por: Takahara, Yusuke, et al.
Publicado: (2018)

Improved time in range and postprandial hyperglycemia with canagliflozin in combination with teneligliptin: Secondary analyses of the CALMER study
por: Cho, Kyu Yong, et al.
Publicado: (2021)

Clinical Pharmacology and Pharmacokinetics of Levetiracetam
por: Wright, Chanin, et al.
Publicado: (2013)

Diabetes Research and Clinical Practice and the fight against COVID-19
por: Ceriello, Antonio
Publicado: (2022)

Extracellular vesicle-shuttled miRNAs: a critical appraisal of their potential as nano-diagnostics and nano-therapeutics in type 2 diabetes mellitus and its cardiovascular complications
por: Prattichizzo, Francesco, et al.
Publicado: (2021)

No Significant Changes of Glycemic Control and Renal Function in Patients with Advanced-Stage Diabetic Kidney Disease by Switching from Linagliptin to Teneligliptin
por: Hirai, Keiji, et al.
Publicado: (2021)

Pharmacokinetic and pharmacodynamic evaluation of linagliptin for the treatment of type 2 diabetes mellitus, with consideration of Asian patient populations
por: Ceriello, Antonio, et al.
Publicado: (2016)

The Dipeptidyl Peptidase-4 Inhibitor Teneligliptin Attenuates Hepatic Lipogenesis via AMPK Activation in Non-Alcoholic Fatty Liver Disease Model Mice
por: Ideta, Takayasu, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_i3ccj6m7rrm97aqdr1u2o4cg7h